LENZ vs LLY vs NVO vs PRPH

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus -35. 8% for ProPhase Labs, Inc. (PRPH). Novo Nordisk A/S (NVO) offers the better valuation at 12. 2x trailing P/E (2. 0x forward), making it the more compelling value choice. Analysts rate LENZ Therapeutics, Inc. (LENZ) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novo Nordisk A/S (NVO) is the cheapest at 12.

2x versus Eli Lilly and Company at 47. 8x. On forward P/E, Novo Nordisk A/S is actually cheaper at 2. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novo Nordisk A/S wins at 0. 10x versus Eli Lilly and Company's 1. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +413.

8%, compared to -76. 5% for LENZ Therapeutics, Inc. (LENZ). Over 10 years, the gap is even starker: LLY returned +1450% versus LENZ's -76. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.

52β versus ProPhase Labs, Inc. 's 1. 98β — meaning PRPH is approximately 280% more volatile than LLY relative to the S&P 500. On balance sheet safety, LENZ Therapeutics, Inc. (LENZ) carries a lower debt/equity ratio of 0% versus 2% for ProPhase Labs, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus -35. 8% for ProPhase Labs, Inc. (PRPH). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -21. 8% for LENZ Therapeutics, Inc.. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus -430. 3% for LENZ Therapeutics, Inc. — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -477. 5% for LENZ. At the gross margin level — before operating expenses — LENZ leads at 96. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Novo Nordisk A/S (NVO) is the more undervalued stock at a PEG of 0. 10x versus Eli Lilly and Company's 1. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Novo Nordisk A/S (NVO) trades at 2. 0x forward P/E versus 30. 0x for Eli Lilly and Company — 28. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LENZ: 95. 1% to $12. 00.

In this comparison, NVO (4.

1% yield), LLY (0. 5% yield) pay a dividend. LENZ, PRPH do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 0. 5% yield, +1450% 10Y return). ProPhase Labs, Inc. (PRPH) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1450%, PRPH: +23. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LENZ is a small-cap quality compounder stock; LLY is a mega-cap high-growth stock; NVO is a mid-cap deep-value stock; PRPH is a small-cap quality compounder stock. LLY, NVO pay a dividend while LENZ, PRPH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.